TOLLIP , MUC5B , and the Response to N -Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Rationale: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown etiology. The genes TOLLIP and MUC5B play important roles in lung host defense, which is an immune process influenced by oxidative signaling. Whether polymorphisms in TOLLIP and MUC5B modify the effect of immunosuppressive and antioxidant therapy in individuals with IPF is unknown. Objectives: To determine whether single-nucleotide polymorphisms (SNPs) within TOLLIP and MUC5B modify the effect of interventions in subjects participating in the Evaluating the Effectiveness of Prednisone, Azathioprine, and N-Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis (PANTHER-IPF) clinical trial. Methods: SNPs within TOLLIP (rs5743890/rs5743894/rs5743854/rs3750920) and MUC5B (rs35705950) were genotyped. Interaction modeling was conducted with multivariable Cox regression followed by genotype-stratified survival analysis using a composite endpoint of death, transplantation, hospitalization, or a decline of ≥10% in FVC. Measurements and Main Results: Significant interaction was observed between N-acetylcysteine (NAC) therapy and rs3750920 within TOLLIP (Pinteraction = 0.001). After stratifying by rs3750920 genotype, NAC therapy was associated with a significant reduction in composite endpoint risk (hazard ratio, 0.14; 95% confidence interval, 0.02–0.83; P = 0.03) in those with a TT genotype, but a nonsignificant increase in composite endpoint risk (hazard ratio, 3.23; 95% confidence interval, 0.79–13.16; P = 0.10) was seen in those with a CC genotype. These findings were then replicated in an independent IPF cohort. Conclusions: NAC may be an efficacious therapy for individuals with IPF with an rs3750920 (TOLLIP) TT genotype, but it was associated with a trend toward harm in those with a CC genotype. A genotype-stratified prospective clinical trial should be conducted before any recommendation regarding the use of off-label NAC to treat IPF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationRegression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,621
Regulation of lung injury and repair by Toll-like receptors and hyaluronan
Jiang, D., Liang, J., Fan, J., Yu, S., Chen, S., Luo, Y., Prestwich, G. D., Mascarenhas, M. M., Garg, H. G., Quinn, D. A., et al. (2005) · Nature Medicine · doi:10.1038/nm1315 · Cited by 1,401
Imai, Y., Kuba, K., Neely, G. G., Yaghubian-Malhami, R., Perkmann, T., van Loo, G., Ermolaeva, M., Veldhuizen, R., Leung, Y. H. C., Wang, H., et al. (2008) · Cell · doi:10.1016/j.cell.2008.02.043 · Cited by 1,356
SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap
Johnson, A. D., Handsaker, R. E., Pulit, S. L., Nizzari, M. M., O'Donnell, C. J., & de Bakker, P. I. W. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn564 · Cited by 1,330
A Common MUC5B Promoter Polymorphism and Pulmonary Fibrosis
Seibold, M. A., Wise, A. L., Speer, M. C., Steele, M. P., Brown, K. K., Loyd, J. E., Fingerlin, T. E., Zhang, W., Gudmundsson, G., Groshong, S. D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013660 · Cited by 1,198
Self-citationRefSeq: an update on mammalian reference sequences
Pruitt, K. D., Brown, G. R., Hiatt, S. M., Thibaud-Nissen, F., Astashyn, A., Ermolaeva, O., Farrell, C. M., Hart, J., Landrum, M. J., McGarvey, K. M., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1114 · Cited by 945
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., Cosgrove, G. P., Lynch, D., Groshong, S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2609 · Cited by 809
Self-citationMuc5b is required for airway defence
Roy, M. G., Livraghi-Butrico, A., Fletcher, A. A., McElwee, M. M., Evans, S. E., Boerner, R. M., Alexander, S. N., Bellinghausen, L. K., Song, A. S., Petrova, Y. M., et al. (2014) · Nature · doi:10.1038/nature12807 · Cited by 764
Self-citationNoth, I., Zhang, Y., Ma, S.-F., Flores, C., Barber, M., Huang, Y., Broderick, S. M., Wade, M. S., Hysi, P., Scuirba, J., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70045-6 · Cited by 614
Self-citationNegative Regulation of Toll-like Receptor-mediated Signaling by Tollip
Zhang, G., & Ghosh, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109537200 · Cited by 592
The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis
Molyneaux, P. L., Cox, M. J., Willis-Owen, S. A. G., Mallia, P., Russell, K. E., Russell, A.-M., Murphy, E., Johnston, S. L., Schwartz, D. A., Wells, A. U., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0541oc · Cited by 567
Self-citationInvolvement of Reactive Oxygen Species in Toll-Like Receptor 4-Dependent Activation of NF-κB
Asehnoune, K., Strassheim, D., Mitra, S., Kim, J. Y., & Abraham, E. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2522 · Cited by 562
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401739 · Cited by 505
Peljto, A. L., Zhang, Y., Fingerlin, T. E., Ma, S.-F., Garcia, J. G. N., Richards, T. J., Silveira, L. J., Lindell, K. O., Steele, M. P., Loyd, J. E., et al. (2013) · JAMA · doi:10.1001/jama.2013.5827 · Cited by 453
Self-citationHan, M. K., Zhou, Y., Murray, S., Tayob, N., Noth, I., Lama, V. N., Moore, B. B., White, E. S., Flaherty, K. R., Huffnagle, G. B., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70069-4 · Cited by 411
Self-citationOccupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis
Hubbard, R., Lewis, S., Richards, K., Johnston, I., & Britton, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90465-1 · Cited by 318
Herpesvirus DNA Is Consistently Detected in Lungs of Patients with Idiopathic Pulmonary Fibrosis
Tang, Y.-W., Johnson, J. E., Browning, P. J., Cruz-Gervis, R. A., Davis, A., Graham, B. S., Brigham, K. L., Oates, J. A., Loyd, J. E., & Stecenko, A. A. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.6.2633-2640.2003 · Cited by 311
Behr, J., Kreuter, M., Hoeper, M. M., Wirtz, H., Klotsche, J., Koschel, D., Andreas, S., Claussen, M., Grohé, C., Wilkens, H., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00217614 · Cited by 247
Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials
Raghu, G., Collard, H. R., Anstrom, K. J., Flaherty, K. R., Fleming, T. R., King, T. E., Martinez, F. J., & Brown, K. K. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201201-0006pp · Cited by 242
Self-citationA Variant in the Promoter of MUC5B and Idiopathic Pulmonary Fibrosis
Zhang, Y., Noth, I., Garcia, J. G. N., & Kaminski, N. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1013504 · Cited by 214
Self-citationDe Flora, S., Grassi, C., & Carati, L. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10071535 · Cited by 195
Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis
Perez-Giraldo, C. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/39.5.643 · Cited by 156
Shah, J. A., Vary, J. C., Chau, T. T. H., Bang, N. D., Yen, N. T. B., Farrar, J. J., Dunstan, S. J., & Hawn, T. R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103541 · Cited by 141
Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function
Schmidt, S. L., Tayob, N., Han, M. K., Zappala, C. J., Kervitsky, D. J., Murray, S., Wells, A. U., Brown, K. K., Martínez, F. J., & Flaherty, K. R. (2013) · CHEST Journal · doi:10.1378/chest.13-0844 · Cited by 112
Durheim, M. T., Collard, H. R., Roberts, R. S., Brown, K. K., Flaherty, K. R., King, T. E., Palmer, S. M., Raghu, G., Snyder, L. D., Anstrom, K. J., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00093-4 · Cited by 87
Self-citationToll like receptor-4 expression in lipopolysaccharide induced lung inflammation.
Janardhan, K. S., McIsaac, M., Fowlie, J. G., Shrivastav, A., Caldwell, S. J., Sharma, R. K., & Singh, B. (2006) · PubMed · doi:10.14670/hh-21.687 · Cited by 73
Sakamoto, S., Muramatsu, Y., Satoh, K., Ishida, F., Kikuchi, N., Sano, G., Sugino, K., Isobe, K., Takai, Y., & Homma, S. (2015) · Respirology · doi:10.1111/resp.12477 · Cited by 70
Association Between Occupational Dust Exposure and Prognosis of Idiopathic Pulmonary Fibrosis
Lee, S. H., Kim, D. S., Kim, Y. W., Chung, M. P., Uh, S. T., Park, C. S., Jeong, S. H., Park, Y. B., Lee, H. L., Song, J. S., et al. (2015) · Chest · doi:10.1378/chest.14-0994 · Cited by 65
Expression of toll-like receptor 2 and 4 in lipopolysaccharide-induced lung injury in mouse
Saito, T., Yamamoto, T., Kazawa, T., Gejyo, H., & Naito, M. (2005) · Cell and Tissue Research · doi:10.1007/s00441-005-1113-9 · Cited by 55
Collard, H. R., Brown, K. K., Martínez, F. J., Raghu, G., Roberts, R., & Anstrom, K. J. (2014) · CHEST Journal · doi:10.1378/chest.14-0492 · Cited by 35
Self-citationOddera, S., Silvestri, M., Sacco, O., Eftimiadi, C., & Rossi, G. (1994) · PubMed · Cited by 28
Santiago, F. M., Bueno, P., Olmedo, C., Muffak-Granero, K., Comino, A., Serradilla, M., Mansilla, A., Villar, J. M., Garrote, D., & Ferrón, J. A. (2008) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.08.103 · Cited by 27
A review on the design and reporting of studies on drug–gene interaction
Smits, K. M., Schouten, J., Smits, L. J. M., Stelma, F. F., Nelemans, P. J., & Prins, M. H. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.01.001 · Cited by 24
Misspecification of Cox regression models with composite endpoints
Wu, L., & Cook, R. J. (2012) · Statistics in Medicine · doi:10.1002/sim.5436 · Cited by 22
Research works printed but not linked: 1
- Oldham, 2015, Genetic heterogeneity among patients enrolled in the PANTHER-IPF clinical trial [abstract], Am J Respir Crit Care Med, 191, A2162
Cited by
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis
Moss, B. J., Ryter, S. W., & Rosas, I. O. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-030240 · Cited by 821
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
Spagnolo, P., Kropski, J. A., Jones, M. G., Lee, J. S., Rossi, G., Karampitsakos, T., Maher, T. M., Tzouvelekis, A., & Ryerson, C. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107798 · Cited by 636
Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.170 · Cited by 402
Metadata
- Authors
- Oldham, J. M., Ma, S.-F., Martinez, F. J., Anstrom, K. J., Raghu, G., Schwartz, D. A., Valenzi, E., Witt, L., Lee, C., Vij, R., Huang, Y., Strek, M. E., & Noth, I.
- Affiliations
- University of Chicago (US)
- Department of Internal Medicine, Weill Cornell Medical School, New York City, New York
- Duke University (US)
- University of Washington Medical Center (US)
- University of Colorado Denver (US)
- Corresponding author
- Oldham, Justin M.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-12
- Volume
- 192
- Issue
- 12
- Pages
- 1475-1482
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC4731723
- OpenAlex
- W1920916096
- Cited by
- 341
- References
- 38
- Citations by year
- 2026: 13 · 2025: 21 · 2024: 46 · 2023: 30 · 2022: 34 · 2021: 32 · 2020: 40 · 2019: 29 · 2018: 25 · 2017: 33 · 2016: 34 · 2015: 3
- FWCI
- 25.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Balbach family, together with National Institutes of Health (U10 HL080513, T32 HL007605)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, Tollip, MUC5B, N-acetylcysteine, single nucleotide polymorphisms, gene-environment interaction, antioxidant therapy, immunosuppressive therapy, prednisone, azathioprine, lung function decline, oxidative stress, lung transplantation
- MeSH terms
- Acetylcysteine, Aged, Female, Humans, Male, Risk, Cohort Studies, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Intracellular Signaling Peptides and Proteins, Idiopathic Pulmonary Fibrosis, Mucin-5B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.